Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCWB NASDAQ:JBIO NASDAQ:PRTG NASDAQ:TNFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCWBHCW Biologics$4.62+2.4%$4.72$3.55▼$100.80$6.49M0.66114,408 shs25,040 shsJBIOJade Biosciences$7.49+2.3%$8.85$6.57▼$105.00$6.15M1.03138,734 shs77,779 shsPRTGPortage Biotech$9.30-6.7%$6.40$2.10▼$23.01$10.46M0.2438,969 shs121,342 shsTNFATNF Pharmaceuticals$0.10-1.6%$0.13$0.08▼$2.16$1.40M1.8280.57 million shs12.56 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCWBHCW Biologics+2.44%+11.86%+6.94%-19.23%-80.72%JBIOJade Biosciences+2.32%+8.71%-28.73%+748,999,900.00%+748,999,900.00%PRTGPortage Biotech-6.72%+71.59%+58.16%+13.97%+189.00%TNFATNF Pharmaceuticals-1.63%-4.16%-23.36%-48.57%+9,679,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCWBHCW Biologics2.8473 of 5 stars3.55.00.00.00.63.30.0JBIOJade Biosciences1.5687 of 5 stars3.50.00.00.00.01.70.6PRTGPortage Biotech0.3301 of 5 stars0.04.00.00.00.01.70.0TNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCWBHCW Biologics 3.00Buy$35.00657.58% UpsideJBIOJade Biosciences 3.00Buy$15.00100.27% UpsidePRTGPortage Biotech 0.00N/AN/AN/ATNFATNF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TNFA, PRTG, JBIO, and HCWB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.005/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCWBHCW Biologics$2.57M2.59N/AN/A($6.08) per share-0.76JBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/APRTGPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$2.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)JBIOJade Biosciences-$69.63M-$59.65N/A∞N/AN/A-60.01%-54.32%N/APRTGPortage Biotech-$6.77M-$41.65N/A∞N/AN/AN/AN/A8/26/2025 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$6.67N/A∞N/AN/A-97.38%-37.37%8/18/2025 (Estimated)Latest TNFA, PRTG, JBIO, and HCWB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCWBHCW BiologicsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCWBHCW BiologicsN/A0.070.07JBIOJade BiosciencesN/A32.0132.01PRTGPortage BiotechN/A2.022.02TNFATNF PharmaceuticalsN/A1.371.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCWBHCW Biologics2.96%JBIOJade BiosciencesN/APRTGPortage Biotech13.36%TNFATNF Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipHCWBHCW Biologics42.70%JBIOJade Biosciences24.90%PRTGPortage Biotech42.07%TNFATNF Pharmaceuticals0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCWBHCW Biologics401.44 million825,000Not OptionableJBIOJade Biosciences20840,000632,000N/APRTGPortage Biotech61.05 million608,000OptionableTNFATNF Pharmaceuticals614.18 million14.12 millionN/ATNFA, PRTG, JBIO, and HCWB HeadlinesRecent News About These CompaniesTNF Pharmaceuticals Inc Ordinary Shares TNFA - MorningstarJuly 11, 2025 | morningstar.comMTNF Pharmaceuticals, Inc. (TNFA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory DiseaseJune 25, 2025 | finance.yahoo.comTNF Pharmaceuticals Amends Bylaws to Alter Voting RulesMay 9, 2025 | tipranks.comTNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsMay 8, 2025 | businesswire.comTNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comTNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentApril 22, 2025 | finance.yahoo.comTNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishApril 22, 2025 | msn.comTNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025April 17, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. Common Stock (TNFA) Short InterestApril 3, 2025 | nasdaq.comTNF Pharmaceuticals faces Nasdaq delisting over priceMarch 23, 2025 | investing.comTNF Pharmaceuticals, Inc. Common StockMarch 20, 2025 | fxempire.comFTNF Pharmaceuticals shares R&D progress on IsomyosamineMarch 12, 2025 | uk.investing.comTNF Pharmaceuticals initiates isomyosamine trialFebruary 25, 2025 | markets.businessinsider.comTNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha InhibitorFebruary 25, 2025 | businesswire.comTNFA stock touches 52-week low at $0.48 amid market challengesFebruary 14, 2025 | msn.comTNFA stock touches 52-week low at $1.02 amid market challengesJanuary 30, 2025 | msn.comHow Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?January 30, 2025 | bovnews.comBTNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss TreatmentJanuary 29, 2025 | tmcnet.comTNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1sJanuary 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, PRTG, JBIO, and HCWB Company DescriptionsHCW Biologics NASDAQ:HCWB$4.62 +0.11 (+2.44%) Closing price 08/8/2025 03:54 PM EasternExtended Trading$4.49 -0.13 (-2.81%) As of 08/8/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Jade Biosciences NASDAQ:JBIO$7.49 +0.17 (+2.32%) As of 08/8/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Portage Biotech NASDAQ:PRTG$9.30 -0.67 (-6.72%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$8.87 -0.43 (-4.58%) As of 08/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.TNF Pharmaceuticals NASDAQ:TNFA$0.10 0.00 (-1.63%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.10 0.00 (-0.52%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
